Navigation Links
Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
Date:4/23/2009

FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's breast cancer menu

ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc., (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has been granted an exclusive intellectual property license from the Indiana University Research and Technology Corporation (IURTC) for the rights to commercialize the FOXA1 biomarker, which predicts the likelihood of recurrence and long-term, disease-free breast cancer survival. The licensing of this intellectual property further strengthens Clarient's deep menu of molecular tests for breast cancer and will complement the Clarient Insight(R) Dx Breast Cancer Profile, which is expected to be released soon.

The FOXA1 marker, also known as forkhead box A1, is a gene known to cause breast cancer. Recent data presented at the 2009 USCAP (United States and Canadian Academy of Pathology) meeting demonstrated that the expression of FOXA1, now known to be an estrogen receptor associated transcription factor, correlated with Oncotype Dx(R) when performed in patient samples from Indiana University. In this clinical study of 79 ER-positive, node-negative breast cancer patients, researchers found that FOXA1 expression identified the same low risk, ER-positive, node-negative patients who can be spared toxic chemotherapy (P=0.002). Researchers concluded Oncotype Dx and the FOXA1 marker can potentially be used interchangeably if further validation studies confirm t
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
11. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... 4, 2011 Kylin Therapeutics, Inc., a leading ... received a notice of allowance from United States ... U.S. patent application. This newly allowed patent broadly ... expanded areas on Kylin,s proprietary nanoparticle technology platform, ...
... DIEGO, Oct. 4, 2011 Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, today announced the launch of its ... genes associated with drug absorption, distribution, metabolism, and excretion ... set of pre-designed single nucleotide polymorphisms (SNP), insertions and ...
... October 4, 2011 Funds to Advance ... a clinical stage European biotechnology company addressing unmet medical ... million ($20 million) in a Series B funding round ... Sofinnova Partners, as well as private Italian investors, joined ...
Cached Biology Technology:Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 3Creabilis Raises €15M ($20M) in Series B Fundraising Round 2
(Date:7/9/2014)... is one of the amphibians with the highest distribution ... areas of water where it comes into contact with ... Research carried out by the Spaniard Germn Orizaola from ... of these frogs have developed a defensive response to ... larger bodies if they co-exist with the crayfish. , ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3Managing the data jungle 2Managing the data jungle 3
... State University scientists and colleagues have completed the genome ... most common and destructive plant parasites - Meloidogyne ... as the northern root-knot nematode. The research could ... to manage the ubiquitous parasitic worm, which, along with ...
... -- Florida State University,s Center for Advanced Power Systems ... to transform the nation,s electric power systems. CAPs is ... of 69 leading companies and academic institutions whose goal ... effort to increase the safety, reliability and capacity of ...
... , Plants that grow more slowly stay ... Biology, scientists at the Max Planck Institute for Developmental ... of genes, so-called microRNAs, coordinate growth and aging processes ... TCP transcription factors. These transcription factors in turn influence ...
Cached Biology News:NC State researchers get to root of parasite genome 2NC State researchers get to root of parasite genome 3FSU joins coalition working to improve nation's power grid 2Formula discovered for longer plant life 2
... Medium is formuatled for the growth ... and Sf21 cells. Grace's Insect Mediu, ... it does not contain lactalbumin hydrosylate, ... transfection. Grace's Insect Medium, Supplemented is ...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
...
...
Biology Products: